Category: Evidence Explainers
Plain-English guides to study quality, statistics, evidence hierarchies and scientific uncertainty.
FDA Peptide Compounding Safety Review (2026): BPC-157, TB-500, MOTS-c, CJC-1295 and More
A substance-by-substance guide to the FDA's current peptide compounding safety concerns, including immunogenicity, aggregation, impurities and gaps in human exposure data.
Read analysis →Peptides and Sport: The 2026 WADA Prohibited List Explained
A plain-English map of the peptide-related substances prohibited in sport in 2026, including BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 and MOTS-c.
Read analysis →BPC-157 Australia (2026): TGA Scheduling, Human Evidence, FDA Safety and WADA Status
A source-led guide to BPC-157 in Australia: what Schedule 4 means, what human evidence exists, why online healing claims run ahead of the data, and how…
Read analysis →GLP-3 Australia: What the Term Means, Retatrutide Evidence and TGA Status
What “GLP-3 Australia” usually means, why the term is informal, how it maps to retatrutide’s three receptor targets, and the current TGA position.
Read analysis →Press Release vs Peer-Reviewed Paper: A Six-Question Evidence Check
How to interpret topline trial announcements before the full protocol, tables and peer-reviewed paper are available.
Read analysis →CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows
REIMAGINE 2 published results: HbA1c, safety and trial limits, with sponsor headlines compared against the peer-reviewed phase 3 paper.
Read analysis →Wegovy HD: What the FDA’s 7.2 mg Semaglutide Approval Means—and What It Does Not
The FDA approved a higher-dose semaglutide injection in March 2026. Here is the regulatory fact pattern, safety context and Australian caveat.
Read analysis →How to Read an HPLC Chromatogram: Peaks, Area & Purity
A practical HPLC chromatogram guide: retention time, peak area, baseline integration, system suitability and why area percent is not mass purity.
Read analysis →What Is a Peptide? Peptides vs Proteins, Hormones and Small Molecules
A practical classification guide explaining why peptide, protein, hormone and small-molecule labels overlap—and why mechanism and evidence matter more than marketing.
Read analysis →Tirzepatide vs Semaglutide: What the SURMOUNT-5 Head-to-Head Trial Actually Shows
A careful reading of SURMOUNT-5: design, 72-week weight outcomes, waist outcomes, safety, funding and the limits of one open-label comparison.
Read analysis →